经皮肝穿刺胆道腔内射频消融治疗恶性胆道梗阻安全性的研究进展

The safety of percutaneous transhepatic intraductal radiofrequency ablation for the treatment of malignant biliary obstruction: recent progress in research

经皮经肝胆道引流(PTCD)和自膨式金属支架植入术是目前公认的治疗无法手术切除的恶性胆道梗阻的有效方式,但胆道支架再狭窄明显影响疗效及预后。经皮肝穿刺胆道腔内射频消融(radiofrequency ablation)能够与胆道支架联合应用,延长胆道支架通畅时间,同时对狭窄段的局部肿瘤进行控制,提高恶性胆道梗阻的治疗效果。作为一种新的治疗方法,安全性尤其重要,本文就经皮肝穿刺胆道腔内RFA联合胆道支架治疗恶性胆道梗阻的安全性进行综述。

At present, the percutaneous transhepatic cholangiodrainage（PTCD） and the self-expandable metal stent implantation are commonly recognized as an effective treatment for inoperable malignant biliary obstruction, but the restenosis of biliary stent significantly affect the therapeutic result and prognosis. Percutaneous transhepatic intraductal radiofrequency ablation can be used together with biliary stent implantation, which can prolong the patency time of biliary stent and control the local tumor at the narrowed segment, thus, the therapeutic effect of malignant biliary obstruction can be reliably improved. As a kind of newly- developed therapy, its clinical safety is especially important. This paper aims to make a review about the safety of percutaneous transhepatic intraductal radiofrequency ablation combined with biliary stent implantation in treating malignant biliary obstruction.